Assertio Q2 sales up 13% to $40.1M; closes Spectrum buy; withdraws guidance on generic Indocin

Assertio Holdings, Inc.

2023-Q2 EPS reported $0.09 revenue$83,457,000

Net product sales $40.1M (+13% YoY); GAAP net income $8.5M ($0.13 EPS), adjusted EPS $0.19 vs $0.28 YoY.
Acquisition of Spectrum closed July 31; ROLVEDON Q2 sales $21.0M, launch trajectory strong.
Cash from operations $18.6M; cash and equivalents $70.2M at quarter end.
2023 financial guidance withdrawn after FDA approval of generic indomethacin suppository.
SG&A $16.8M, up from $10.5M, includes $3.4M transaction costs vs $2.0M insurance benefit last year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Assertio Holdings, Inc. reported second quarter ended June 30, 2023 results: revenue $40.1 million, net income $8.5 million, EPS $0.13.

Period: second quarter ended June 30, 2023
Revenue: $40.1 million
Net income: $8.5 million
EPS: $0.13
Result: reported results

Exact text from the filing

Per Share (Non-GAAP) 2 $ 0.19 $ 0.28 $ 0.48 $ 0.66 Second quarter results included the following as compared to the prior year quarter: • Net product sales increased 13% , to $40.1 million. ◦ Increased sales of Indocin and Otrexup plus the addition of Sympazan more than offset the expected decline in Cambia. ◦ Sympazan achieved new peaks in both quarterly and

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Assertio Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001808665-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.